Reading the tape
NASDAQ: ANAB
AnaptysBio, Inc.
Healthcare · Biotechnology
Market Cap
$3.01B
52w High
$71.67
52w Low
$11.40
P/E
-146.55
Volume
578.03K
Outstanding Shares
43.12M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 404.92%Revenue (TTM): 157.01%FCF (TTM): 114.45%P/S: 37th pct
What changed
The stock rose 404.92% over the last year. Revenue grew 157.01% over the trailing twelve months. Operating margin moved from -125.93% to 20.42%. Free cash flow grew 114.45% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 37th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at 20.42%. Revenue grew 157.01% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
CEODaniel R. Faga
SectorHealthcare
IndustryBiotechnology
Employees136
IPO dateJan 26, 2017
Valuation
Forward P/E—
EV/EBITDA13.40
Enterprise value$674.06M
Stock splits
Apr 20, 2026↑ Forward
Every 2 shares became 3
Profitability & growth
Revenue growth151.08%
Gross margin98.97%▲224.50%vs FY2024
Operating margin20.42%▲116.21%vs FY2024
ROE-35.56%▲82.65%vs FY2024
Analyst consensus
RatingBuy
Target price$73.88▲5.88%
16
Buy
6
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 4, 2026
Q2 FY26 · EPS est -$0.94 · Revenue est $18.86M
View